About Synageva Biopharma (NASDAQ:GEVA)
Synageva BioPharma Corp. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic products for the treatment of rare diseases. The Company has a pipeline of protein therapeutic programs for rare diseases. Its lead product is Kanuma (sebelipase alfa) being developed for the treatment of lysosomal acid lipase deficiency (LAL Deficiency). The Company's other product candidates under development include SBC-103, a first-mover enzyme replacement therapy program for mucopolysaccharidosis IIIB (MPS IIIB, also known as Sanfilippo B syndrome) and SBC-105, which is a first-mover enzyme therapy in preclinical development for rare disorders of calcification, including the indication generalized calcification in infants (GACI). The Company also has additional first-mover and potentially bio-superior protein therapeutic pipeline programs for other rare diseases at different stages of preclinical development.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on Equity-39.57%
Return on Assets-37.57%
Synageva Biopharma (NASDAQ:GEVA) Frequently Asked Questions
What is Synageva Biopharma's stock symbol?
Synageva Biopharma trades on the NASDAQ under the ticker symbol "GEVA."
How were Synageva Biopharma's earnings last quarter?
Synageva Biopharma Corp (NASDAQ:GEVA) released its quarterly earnings data on Thursday, February, 26th. The biopharmaceutical company reported ($1.73) earnings per share for the quarter, missing analysts' consensus estimates of ($1.71) by $0.02. The biopharmaceutical company earned $1.24 million during the quarter, compared to the consensus estimate of $1.25 million. Synageva Biopharma had a negative net margin of 6,429.45% and a negative return on equity of 39.57%. View Synageva Biopharma's Earnings History.
Has Synageva Biopharma been receiving favorable news coverage?
Press coverage about GEVA stock has been trending somewhat positive on Sunday, according to Accern Sentiment Analysis. The research firm identifies negative and positive media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Synageva Biopharma earned a news sentiment score of 0.13 on Accern's scale. They also gave news stories about the biopharmaceutical company an impact score of 45.77 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
How do I buy shares of Synageva Biopharma?
Shares of GEVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Synageva Biopharma?
Synageva Biopharma's mailing address is 33 Hayden Ave, LEXINGTON, MA 02421-7972, United States. The biopharmaceutical company can be reached via phone at +1-781-3579900.
MarketBeat Community Rating for Synageva Biopharma (GEVA)MarketBeat's community ratings are surveys of what our community members think about Synageva Biopharma and other stocks. Vote "Outperform" if you believe GEVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GEVA will underperform the S&P 500 over the long term. You may vote once every thirty days.